COVID-19 Drug Remdesivir Could Cost Up to $3,120 Per Patient, Maker Says
MONDAY, June 29, 2020 — The maker of remdesivir, the first drug that showed promise in treating coronavirus infections, will charge U.S. hospitals $3,120 for a patient with private insurance, the drug company announced Monday.
Because of how the U.S. health care system is designed and the discounts that government health care programs like the VA and Medicaid will expect, the price for private insurance companies will be $520 per vial, Gilead Sciences explained in a letter. Most COVID-19 patients would need six vials of the drug over five days, the company said.
A lower price — $390 per vial — will be offered to other governments in developed countries around the world, Gilead added.
“As the world continues to reel from the human, social and economic impact of this pandemic, we believe that pricing remdesivir well below value is the right and responsible thing to do,” Gilead Chairman and CEO Daniel O’Day said in the company’s letter. (See link for article)
Our “authorities” have a financial conflict of interest in this expensive treatment: https://principia-scientific.org/a-tale-of-2-drugs-deep-state-chose-money-power-over-lives/ Half of the COVID treatment panel has financial ties to Gilead Sciences: https://covid19treatmentguidelines.nih.gov/panel-financial-disclosure/
Approximately $70 million in U.S. taxpayer funding began Gilead’s partnership with the U.S. Army, Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH) to develop remdesivir. Initially for treating Ebola, it failed to show benefit and was shelved. If remdesivir is used to treat COVID-19, Gilead shareholders, not the taxpayers, will profit.
Going back to 1997, Donald Rumsfeld chaired the Board of Directors at Gilead and after 2001 he held share packages valued at $5-25 Million. Gilead originally developed Tamiflu. George P Shultz, US Secretary of State also was on the board. He sold stocks at a value of more than $7 million. CA governor’s Pete Wilson’s wife also sat on the board.
“‘I don’t know of any biotech company that’s’ so politically well-connected [as Gilead],‘ Andrew McDonald, of the analyst firm Think Equity Partners, told Fortune.” (Source: “Virus Mania, How the Medical Industry Continually Invents Epidemics Making Billion Dollar Profits At Our Expense”)
This article also points out an ugly conflict of interest web between Gilead, the manufacturer of Remdesivir and UNITAID which Soros, Gates, and the Clinton Health Access Initiative, are large investors – with Drs. Fauci and Birx associated with the Clinton Health Access initiative. https://www.thegatewaypundit.com/2020/06/stunning-faucis-remdesivir-costs-9-per-dose-will-sold-3000-per-dose-china-company-linked-soros-will-also-mass-produce-drug/ And of course, Dr. Fauci has worked with Gilead for a long, long time.
Government employees should not be allowed to have financial ties to manufacturing companies and then turn around and make public health policy.
Remdesivir isn’t cheap. It costs between $520-$390 per vial and will be sold for $3,120 per 6 vial treatment: That’s a lot of money for a drug that hasn’t even been shown to lower viral load.
Hydroxychloroquine in the other hand costs $1 per treatment, while chloroquine costs a measly 30 cents! https://madisonarealymesupportgroup.com/2020/05/11/podcast-evidence-supporting-hcq-azithromycin-for-covid-19/
Early results of the first clinical trial of remdesivir against placebo in coronavirus showed modest benefits, according to The New York Times. Surviving patients given remdesivir were discharged four days sooner than patients given placebo, though no criteria were given for determining improvement. Death rates were not significantly different. About 25% of patients receiving remdesivir had potentially severe side effects, including multiple organ dysfunction, septic shock, acute kidney injury and low blood pressure. Another 23% showed evidence on lab tests of liver damage.
Gilead’s own press release revealed the side effect of acute respiratory failure in 6% of patients in the remdesivir five-day treatment group, and 10.7% of patients in the 10-day treatment group, clearly ominous findings with a drug designed to treat respiratory failure caused by COVID-19.